Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab

  • Usha Bughani,
  • Arindam Saha,
  • Anshu Kuriakose,
  • Reshmi Nair,
  • Ravindra B. Sadashivarao,
  • Rasika Venkataraman,
  • Swati Patel,
  • Anuja Tushar Deshchougule,
  • Kumar S. Satish,
  • Enrique Montero,
  • Harish V. Pai,
  • Dinesh V. Palanivelu,
  • Ramakrishnan Melarkode,
  • Pradip Nair

S3 Fig is incorrect. In panels A and B, the legend for Iso Ab and Unstimulated have been interchanged. Please view the corrected S3 Fig below.

Supporting information

S3 Fig. CD6 receptor on lymphocytes is not internalised and is occupied with Itolizumab.

Human PBMCs were left unstimulated or stimulated with soluble anti CD3 0.5 ng/ml (OKT-3) in presence of Iso Ab or Itolizumab at 10 μg/mL for 3 days. Post stimulation, cells were harvested and stained with anti CD6 Ab, MEM98 clone (A) and anti-human IgG, Fc specific (B). In panel A, since the CD6 receptor is occupied with Itolizumab, MEM 98 (commercially available anti CD6 D1) could not bind in Itolizumab treated groups and hence no signal is observed. The positive signal with anti-human IgG, in Itolizumab treated group in panel B suggests that Itolizumab is occupying CD6 receptor on lymphocyte surface. Data is representative of at least 3 independent experiments.

https://doi.org/10.1371/journal.pone.0192335.s001

(DOCX)

Reference

  1. 1. Bughani U, Saha A, Kuriakose A, Nair R, Sadashivarao RB, Venkataraman R, et al. (2017) T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS ONE 12(7): e0180088. https://doi.org/10.1371/journal.pone.0180088 pmid:28672038

Citation: Bughani U, Saha A, Kuriakose A, Nair R, Sadashivarao RB, Venkataraman R, et al. (2018) Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS ONE 13(1): e0192335. https://doi.org/10.1371/journal.pone.0192335

Published: January 30, 2018

Copyright: © 2018 Bughani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.